Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Maurizio Zangari

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Zangari, Maurizio

PropertyValue
research overview Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.

One or more keywords matched the following items that are connected to Zangari, Maurizio

Item TypeName
Academic Article Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
Academic Article DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Academic Article Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Academic Article Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
Academic Article Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Academic Article Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Academic Article Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Academic Article Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Academic Article Hyperammonemia and encephalopathy in patients with multiple myeloma.
Academic Article Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Academic Article Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Academic Article Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
Academic Article Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Academic Article Thrombotic events in patients with cancer receiving antiangiogenesis agents.
Academic Article Effect of time to infusion of autologous stem cells (24 vs. 48?h) after high-dose melphalan in patients with multiple myeloma.
Academic Article Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Academic Article Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Academic Article The Arkansas approach to therapy of patients with multiple myeloma.
Academic Article A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
Academic Article Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Academic Article Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Academic Article Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Academic Article Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Academic Article Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Academic Article Estimation of daily proteinuria in patients with multiple myeloma by using the protein-to-creatinine ratio in random urine samples.
Concept Patient Participation
Concept Patient Selection
Concept Patients
Academic Article Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
Academic Article Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Academic Article FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients.
Grant UARK 2002-37, An Open Label Phase II Extension Study to Assess the Long-Term Safety and Tolerability of MRA Given to Patients with Multiple Myeloma
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Academic Article Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Academic Article Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Academic Article Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma.
Academic Article Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.
Academic Article Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Academic Article The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
Academic Article Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Academic Article A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Academic Article CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients.

Search Criteria
  • Patients